'We kept at it': Jef­frey Blue­stone plots late-stage come­back af­ter teplizum­ab shown to de­lay type 1 di­a­betes

Late-stage da­ta pre­sent­ed at the Amer­i­can Di­a­betes As­so­ci­a­tion an­nu­al meet­ing in 2010 pushed Eli Lil­ly to put a crimp on teplizum­ab as the phar­ma gi­ant found it un­able to re­set the clock on new­ly di­ag­nosed type 1 di­a­betes. At the same con­fer­ence but in dif­fer­ent hands nine years lat­er, the drug is mak­ing a crit­i­cal come­back by scor­ing suc­cess in an­oth­er niche: de­lay­ing the on­set of the dis­ease.

In a Phase II tri­al with 76 high-risk in­di­vid­u­als — rel­a­tives of pa­tients with type 1 di­a­betes who have di­a­betes-re­lat­ed au­toan­ti­bod­ies in their bod­ies — teplizum­ab al­most dou­bled the me­di­an time of di­ag­no­sis com­pared to place­bo (48.4 months ver­sus 24.4 months). The haz­ard ra­tio for di­ag­no­sis was 0.41 (p=0.006).

In­ves­ti­ga­tors added that teplizum­ab’s ef­fects seem strongest in the first year, when pro­gres­sion to type 1 di­a­betes was al­so the great­est in the over­all tri­al pop­u­la­tion. In that year, on­ly 3 of 44 teplizum­ab par­tic­i­pants was di­ag­nosed, com­pared to 14 of 32 in the place­bo arm. All told, the di­ag­no­sis rates at the end of the tri­al were 43% (19/44) and 72% (23/32), re­spec­tive­ly.

With less than three years of me­di­an fol­low-on af­ter a 14-day reg­i­men, the re­sults don’t say much about the po­ten­tial for pre­ven­tion or even cure but do sup­port the idea that im­mune mod­u­la­tion could buy time for pa­tients who ap­pear doomed for a life de­pen­dent on in­sulin.

Teplizum­ab, which tar­gets CD3, is de­signed to di­min­ish CD8+ T lym­pho­cytes’ at­tacks on be­ta cells in the pan­creas, even­tu­al­ly de­plet­ing these in­sulin gen­er­a­tors.

“(T)hese da­ta pro­vide strong al­beit in­di­rect ev­i­dence about the patho­gen­e­sis of be­ta-cell de­struc­tion and the po­ten­tial to mod­i­fy the course of type 1 di­a­betes with new­er bi­o­log­ic agents,” Clif­ford Rosen and Julie In­gelfin­ger of the Maine Med­ical Cen­ter Re­search In­sti­tute wrote in an ac­com­pa­ny­ing ed­i­to­r­i­al in the New Eng­land Jour­nal of Med­i­cine.

It’s al­so a vic­to­ry for Jef­frey Blue­stone of UCSF and Ke­van Herold of Yale, who have main­tained their con­fi­dence in teplizum­ab since they be­gan work­ing on its ap­pli­ca­tion in di­a­betes in the eal­ry 1990s. Blue­stone con­vinced Proven­tion Bio to pick up the drug be­fore jump­ing on its board to help steer the clin­i­cal study. Proven­tion Bio $PRVB surged more than 400% to $22 at one point, end­ing the day up 217%.

“(N)ow the re­al hard work be­gins,” Blue­stone told Sci­ence with re­gards to the next steps.

Re­cruit­ing pa­tients, es­pe­cial­ly chil­dren, might prove a chal­lenge in new place­bo-con­trolled stud­ies. No­tably, the size of this cur­rent tri­al was cut by al­most half due to slow­er-than-ex­pect­ed rates of en­roll­ment. Mov­ing for­ward, large-scale screen­ing ef­forts will al­so be re­quired to ex­tend the drug’s reach to at-risk in­di­vid­u­als with no fam­i­ly his­to­ry of di­a­betes.

“The key next step of course is see­ing whether this drug can cross the fin­ish line through up­com­ing Phase III tri­als and get ap­proved by the FDA. There’s still lots to do – but hope­ful­ly this speeds things up a bit,” Blue­stone added in a state­ment.

Im­age: Jef­frey Blue­stone — UCSF via Park­er

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.

Jim Mellon [via YouTube]

Health­i­er, longer lifes­pans will be a re­al­i­ty soon­er than you think, Ju­ve­nes­cence promis­es as it clos­es $100M round

Earlier this year, an executive from Juvenescence-backed AgeX predicted the field of longevity will eventually “dwarf the dotcom boom.” Greg Bailey, the UK-based anti-aging biotech’s CEO, certainly hopes so.

On Monday, Juvenescence completed its $100 million Series B round of financing. The company is backed by British billionaire Jim Mellon — who wrote his 400-page guide to investing in the field of longevity shortly after launching the company in 2017. Bailey, who served as a board director for seven years at Medivation before Pfizer swallowed the biotech for $14 billion, is joined by Declan Doogan, an industry veteran with stints at Pfizer $PFE and Amarin $AMRN.

AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.